CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $49.4 million, has announced updated data from its Phase 2 clinical ...
The single arm pivotal Phase 2 trials will study the drug combination in hepatocellular carcinoma, small cell lung cancer and colorectal cancer. MAIA’s preclinical results in HCC, with THIO in ...
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback